Champions Oncology, Inc. (CSBR)
NASDAQ: CSBR · Real-Time Price · USD
4.390
+0.090 (2.09%)
Nov 21, 2024, 11:12 AM EST - Market open
Champions Oncology Income Statement
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jul '24 Jul 31, 2024 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 | Apr '20 Apr 30, 2020 | 2019 - 2015 |
| Revenue | 51.66 | 50.16 | 53.87 | 49.11 | 41.04 | 32.12 | Upgrade
|
| Revenue Growth (YoY) | -1.96% | -6.90% | 9.69% | 19.66% | 27.76% | 18.68% | Upgrade
|
| Cost of Revenue | 28.79 | 29.4 | 29.53 | 23.63 | 21.45 | 17 | Upgrade
|
| Gross Profit | 22.87 | 20.75 | 24.34 | 25.48 | 19.59 | 15.12 | Upgrade
|
| Selling, General & Admin | 17.7 | 18.13 | 17.24 | 15.5 | 12.03 | 10.86 | Upgrade
|
| Research & Development | 8.21 | 9.54 | 11.55 | 9.37 | 7.2 | 5.85 | Upgrade
|
| Operating Expenses | 25.91 | 27.68 | 28.79 | 24.87 | 19.23 | 16.71 | Upgrade
|
| Operating Income | -3.04 | -6.92 | -4.45 | 0.61 | 0.37 | -1.59 | Upgrade
|
| Interest Expense | -0.03 | -0.03 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 0.09 | 0.09 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.02 | -0.02 | -0.01 | -0.02 | -0.01 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | - | - | - | - | -0.09 | Upgrade
|
| EBT Excluding Unusual Items | -3 | -6.87 | -4.46 | 0.58 | 0.36 | -1.68 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | - | -0.34 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.44 | -0.44 | - | - | - | 0.05 | Upgrade
|
| Asset Writedown | - | - | -0.81 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.08 | - | Upgrade
|
| Pretax Income | -3.44 | -7.31 | -5.27 | 0.58 | 0.44 | -1.96 | Upgrade
|
| Income Tax Expense | -0.04 | -0.03 | 0.07 | 0.04 | 0.08 | 0.13 | Upgrade
|
| Net Income | -3.4 | -7.28 | -5.34 | 0.55 | 0.36 | -2.09 | Upgrade
|
| Net Income to Common | -3.4 | -7.28 | -5.34 | 0.55 | 0.36 | -2.09 | Upgrade
|
| Net Income Growth | - | - | - | 51.38% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 14 | 14 | 14 | 13 | 13 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 14 | 14 | 14 | 14 | 15 | 12 | Upgrade
|
| Shares Change (YoY) | 0.23% | 0.04% | -4.37% | -2.84% | 23.05% | -15.98% | Upgrade
|
| EPS (Basic) | -0.25 | -0.54 | -0.39 | 0.04 | 0.03 | -0.18 | Upgrade
|
| EPS (Diluted) | -0.25 | -0.54 | -0.39 | 0.04 | 0.02 | -0.18 | Upgrade
|
| EPS Growth | - | - | - | 100.01% | - | - | Upgrade
|
| Free Cash Flow | -2 | -6.97 | 1.1 | 4.11 | -4.96 | 0.69 | Upgrade
|
| Free Cash Flow Per Share | -0.15 | -0.51 | 0.08 | 0.29 | -0.34 | 0.06 | Upgrade
|
| Gross Margin | 44.27% | 41.38% | 45.18% | 51.88% | 47.74% | 47.08% | Upgrade
|
| Operating Margin | -5.89% | -13.80% | -8.26% | 1.24% | 0.89% | -4.94% | Upgrade
|
| Profit Margin | -6.58% | -14.51% | -9.90% | 1.12% | 0.88% | -6.52% | Upgrade
|
| Free Cash Flow Margin | -3.88% | -13.90% | 2.04% | 8.38% | -12.09% | 2.13% | Upgrade
|
| EBITDA | -1.17 | -5.05 | -2.83 | 2.23 | 1.55 | -0.76 | Upgrade
|
| EBITDA Margin | -2.26% | -10.08% | -5.26% | 4.55% | 3.78% | -2.37% | Upgrade
|
| D&A For EBITDA | 1.87 | 1.87 | 1.62 | 1.63 | 1.18 | 0.83 | Upgrade
|
| EBIT | -3.04 | -6.92 | -4.45 | 0.61 | 0.37 | -1.59 | Upgrade
|
| EBIT Margin | -5.89% | -13.80% | -8.26% | 1.24% | 0.89% | -4.94% | Upgrade
|
| Effective Tax Rate | - | - | - | 6.00% | 17.16% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.